Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 0.80 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517412 | 1.00 | ALK (1.00) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL518047 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517293 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517390 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517457 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517784 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517786 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517785 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517503 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL518394 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4721758-A1 | NOVEL MEDICINE FOR TREATING OSTEOSARCOMA | Japanese Foundation For Cancer Research (JP) | 2026-04-08 | — | — | EP | claimed |
| EP-3453392-B1 | THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE | JAPANESE FOUND FOR CANCER RES (JP) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4593956-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-08-06 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| CN-120051302-A | Methods for treating inactivity or chronic thyroid eye disease | 爱尔兰好利恩治疗有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025106903-A1 | THE ROLE OF MIR-15A IN DIAGNOSING AND TREATING PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250146076-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| EP-4100127-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | Horizon Therapeutics Ireland Dac (IE) | 2022-12-14 | — | — | EP | claimed |
| CN-115397518-A | Methods of treating scleroderma and related conditions | 赫瑞森治疗学爱尔兰指定活动公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2022-11-10 | — | — | US | claimed |
| WO-2022225995-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| CN-115175701-A | Methods for treating thyroid eye disease | 爱尔兰霍里森治疗公司 | 2022-10-11 | — | — | CN | claimed |
| US-11419871-B2 | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2022-08-23 | — | — | US | claimed |
| WO-2022165214-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-4021500-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2022-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419871-B2 | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance | EGFR, ALK, ERBB3 | ALK 2/4885EGFR 1/4885IGF1R 212/4885 |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | TPO, TSHR, TRHDE | ALK 3821/4885EGFR 1436/4885IGF1R 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.